

Adrenal Insufficiency Committee meeting 5

Date: 30 November 2022

Location: Virtual meeting

Minutes: Final

Committee members present:	
Benjamin Ellis (BE)	(Present for items 1 – 9)
Helen Simpson (HS)	(Present for items 1 – 9)
Anh Tran (AT)	(Present for items 1 – 9)
Kate Owen (KO)	(Present for items 1 – 9)
Chloe Mezzetti (CM)	(Present for items 1 – 9)
Colin Omorodion (CO)	(Present for items 1 – 9)
Kate Davies (KD)	(Present for items 1 – 9)
Kaz Williams (KW)	(Present for items 1 – 9)
Lisa Shepherd (LS)	(Present for items 1 – 9)
Sally Tollerfield (ST)	(Present for items 1 – 9)
Philip Newland-Jones (PNJ)	(Present for items 1 – 9)
Simon Pearce (SP)	(Present for items 1 – 9)
Nabil Boulos (NB)	(Present for items 1 – 9)
Ranna El Khairi (RK)	(Present for items 4 – 8)
Callum Brown (CB)	(Present for items 1 – 9)
Sally Caruthers (SC)	(Present for items 1 – 9)
Geraint Morris (GM)	(Present for items 1 - 9)

In attendance:		
Alexandra Bonnon (AB)	Health economist	(Present for items 4 – 9)
Benjamin Fletcher (BF)	Technical Analyst, Surveillance Team	(Present for items 1 – 9)
Meena Tafazzoli (MT)	Technical Analyst	(Present for items 1 – 9)
Patrick Langford (PL)	Technical Analyst, Surveillance Team	(Present for items 1 – 9)
Catharine Baden-Daintree (CBD)	Senior Editor	(Present for items 1 – 9)
Saoussen Ftouh (SF)	Senior Research Fellow	(Present for items 1 – 9)
Sharon Swain (SS)	Guideline Lead	(Present for items 1 – 9)
Sophia Kemmis-Betty	Health Economics Lead	(Present for items 1 – 9)
Stephen Deed (SD)	Information Specialist	(Present for item 8)
Tamara Diaz (TD)	Project Manager	(Present for items 1 – 9)

Apologies:

1. Welcome

The Chair welcomed the Committee members and attendees to the fifth meeting on the Adrenal Insufficiency guideline. The Committee members were introduced to new cooptee members of the Committee.

The Chair outlined the objectives of the meeting, which included presentation of the results of the evidence reviews on:

- Information and support
- Pharmacological treatments for the emergency management of adrenal crisis.
- Routine pharmacological management (glucocorticoids) in secondary and tertiary adrenal insufficiency.

The review of recommendations on:

- Routine pharmacological management in secondary and tertiary adrenal insufficiency.

And the discussion of the review protocols for the following questions:

- 2.1 When should adrenal insufficiency be suspected (for example, based on risk factors or symptoms)
- 2.2 When should a person who is having exogenous corticosteroids withdrawn be referred for investigation and management of adrenal insufficiency related to HPA-axis suppression?

2. Confirmation of matter under discussion, and declarations of interest

New declarations made by committee members on meeting day are listed below.

Name	Declaration	Classification	Action
Helen Simpson	Lecture for Drug company – oncology meeting on checkpoint inhibitor planned for January 2023.	Direct Financial	Declare and participate
	Trustee/Council Member Society for Endocrinology (Dec 2022-2026)	Direct Non-Financial	Declare and participate

	Guidance for the prevention and emergency management of adult patients with adrenal insufficiency	Direct Non-Financial	Declare and participate
<p>The Chair and a senior member of the Developer's team noted that the interests noted on the circulated register and those listed above, prevent the following attendees from fully participating in meeting discussions: Helen Simpson, Simon Pearce, Sally Tollerfield and Nabil Boulos.</p>			
3. Confirmation of minutes			
Minutes of guideline committee meeting 4 were confirmed.			
4. Evidence review: information and support			
The clinical and economic evidence was presented for the group's consideration by LM. Recommendations were drafted for this topic, after the committee's discussion of the evidence.			
5. Evidence review: pharmacological treatments for the emergency management of adrenal crisis			
The clinical and economic evidence was presented for the group's consideration, by SF. Recommendations were drafted for this topic, after the committee's discussion of the evidence. See notes above on committee members excluded from discussions due to the conflicts of interest policy.			
6. Discussion of evidence: Routine pharmacological management in secondary and tertiary adrenal insufficiency.			
Recommendations were reviewed for this topic.			
7. Evidence review: Routine pharmacological management (glucocorticoids) in secondary and tertiary Adrenal Insufficiency.			
The clinical and economic evidence was presented for the group's consideration by MT. Recommendations were DRAFTED for this topic, after the committee's discussion of the evidence.			
8. Draft protocols:			
<p>The committee was unable to complete discussions on the following items, they will be raised again for agreement at meeting 6 scheduled for January 2023:</p> <ul style="list-style-type: none"> • 2.1 When should adrenal insufficiency be suspected (for example, based on risk factors or symptoms) • 2.2 When should a person who is having exogenous corticosteroids 			

withdrawn be referred for investigation and management of adrenal insufficiency related to HPA-axis suppression?

9. Any other business

None.

Date of next meeting: 25 January 2023

Location of next meeting: Virtual meeting